Free shipping on all orders over $ 500

RO4987655

Cat. No. M9014

All AbMole products are for research use only, cannot be used for human consumption.

RO4987655 Structure
Synonym:

CH4987655

Size Price Availability Quantity
5mg USD 235  USD235 In stock
10mg USD 375  USD375 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

RO4987655 is an orally active and highly selective MEK inhibitor with an IC50 of 5.2 nM. RO4987655 inhibits proliferation of NCI-H2122 cells in a dose-dependent manner with an IC50 value of 0.0065 μM.

In vivo, RO4987655 is rapidly absorbed with a tmax of ~1 h. Female athymic nude mice are randomized into study groups. The tumors size is estimated with digital caliper and PET scans performed on days 0, 1, and 3 with 1.0, 2.5, and 5.0 mg/kg RO4987655. The vehicle treatment does not inhibit the NCI-H2122 tumor xenograft growth over this time frame. In contrast, RO4987655 treatment results in 119% tumor growth inhibition (TGI) at 1.0 mg/kg, 145% TGI at 2.5 mg/kg and 150% TGI at 5.0 mg/kg on day 3.

Protocol (for reference only)
Cell Experiment
Cell lines human lung adenocarcinoma cell line NCI-H2122
Preparation method The human lung adenocarcinoma cell line NCI-H2122 are maintained in the designated media and indicated concentrations of heat-inactivated fetal bovine serum and L-glutamine. Cells are grown at 37°C in an atmosphere of 5%CO2. Cells are treated with various concentrations of RO4987655 (0.00001, 0.001, 0.1, and 10 μM) for 72 h in 96-well plates and viable cells were quantified with Cell Counting Kit-8.
Concentrations 0.00001, 0.001, 0.1, and 10 μM
Incubation time 72 h
Animal Experiment
Animal models
Formulation
Dosages
Administration
Chemical Information
Molecular Weight 565.28
Formula C20H19F3IN3O5
CAS Number 874101-00-5
Solubility (25°C) DMSO: ≥ 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Tegnebratt T, et al. EJNMMI Res. Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches.

[2] Leijen S, et al. Clin Cancer Res. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

[3] Lee L, et al. Clin Cancer Res. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.

Related MEK Products
Balamapimod

Balamapimod (MKI 833) is a reversible Ras/Raf/MEK inhibitor with potential anti-tumor activity.

PD-334581 

PD-334581 is a MEK1 inhibitor.

Tunlametinib

Tunlametinib, an antineoplastic agent, is a MEK1/2 inhibitor.

Glycinexylidide

Glycinexylidide (GX) is the active metabolite of Lidocaine.

Xantocillin

Xantocillin (Xanthocillin X) is a marine agent extracted from Penicillium commune, induces autophagy through inhibition of the MEK/ERK pathway.

  Catalog
Abmole Inhibitor Catalog




Keywords: RO4987655, CH4987655 supplier, MEK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.